Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A10224581" target="_blank" >RIV/61989592:15110/09:10224581 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients

Popis výsledku v původním jazyce

Homocysteine (HCY)is a risk factor for vascular diseases, cognitive impairment and dementia. Vascular diseases and cognitive impairment worsen the prognosis of Parkinson's disease. Risk of their occurence is advisable to minimize. The mechanism underlying elevated plasma HCY level is the O-methylation of levodopa. This reaction is catalyzed by the enzyme catechol-O-methyltransferase (COMT) and requires S-adenosylmethionine as the methyl donor for the production of S-adenosylhomocysteine, which is rapidly hydrolyzed to HCY. Elevated plasma HCY levels were found in PD patients treated with levodopa. Some animal studies shows., that addition of COMT inhibitors to levodopa should eliminate levodopa induced hyperhomocysteinemia (HHCY). Some of recent retrospective studies confirmed fact, but some of them did not.

Název v anglickém jazyce

Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients

Popis výsledku anglicky

Homocysteine (HCY)is a risk factor for vascular diseases, cognitive impairment and dementia. Vascular diseases and cognitive impairment worsen the prognosis of Parkinson's disease. Risk of their occurence is advisable to minimize. The mechanism underlying elevated plasma HCY level is the O-methylation of levodopa. This reaction is catalyzed by the enzyme catechol-O-methyltransferase (COMT) and requires S-adenosylmethionine as the methyl donor for the production of S-adenosylhomocysteine, which is rapidly hydrolyzed to HCY. Elevated plasma HCY levels were found in PD patients treated with levodopa. Some animal studies shows., that addition of COMT inhibitors to levodopa should eliminate levodopa induced hyperhomocysteinemia (HHCY). Some of recent retrospective studies confirmed fact, but some of them did not.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Parkinsonism and Related Disorders

ISSN

1353-8020

e-ISSN

—

Svazek periodika

2009

Číslo periodika v rámci svazku

15

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

477-478

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—